[MUSIC]
Welcome to the Parishlanab Podcast, the official podcast of the Parishlanab Society.
Exploring topics in Parishlanab Resorters, Awareness, Education and Advocacy.
We are your hosts, Dr. Paola Alberti from University of Milano, Bicocca, Italy, and
Fessings to Zennepark from University of Sydney, Australia.
Welcome to the next episode in the peripheral nerve podcast series, "Understanding
Chemotherapy and Juice peripheral neuropathy".
In this episode, we are delighted to welcome Professor Rosa Velascu, Professor Velascu is
a neurologist and principal investigator at the Neuroncology Group of the Catalan Institute
of oncology at Belvich University Hospital in Barcelona and an adjunct professor at University
Talk, Autónoma de Barcelona. Today, we are excited to discuss the topic of precision
medicine in the IPN, exploring our biomarkers may assist in predicting risk of these disease.
Professor Velascu's research work is focused on neurotoxicity, spanning the spectrum of clinical
studies, biolarka discovery, and guideline development.
She's made major contributions to the study of neurological complications following chemotherapy,
as well as emerging cancer therapies such as amino therapy and Carti cell therapy. Her
work integrates serum biomarkers, neurophysiology, and risk faster assessment to advance personalized
approaches to mitigate neurotoxicity. Today, we're excited to discuss the search for sensitive
biomarkers to define why some patients develop toxicity and others do not, following neurotoxic
chemotherapy, or honor to have you here speaking with us today.
Like a professor Velascu, it's so wonderful to have you here with us today.
Thank you, Paola, and Susanna for the invitation, and we're happy to be here to share my knowledge
and to enjoy this focus.
Thank you so much. If I can start with the first question, can you provide an overview
of key biomarkers relevant to predicted monitors here, including genetics, proteomic, metabolomic,
or electrophysiological?
Yes, of course. When discussing biomarkers in CypN, I usually find it helpful to separate
them into four groups, clinical, neurophysiological, block-based, and imaging biomarkers.
And technical markers and risk factors include redomboaids, diabetes, practicing neuropathy,
comorbidities, or previous exposure to neurotoxic chemotherapy. And these factors are in
form because they help us understand the patient's baseline vulnerability. However, we have seen
that most of them are not as strong enough on their own to predict severe CypN in individual
patients. So they are more useful as part of the general risk profile than as isolated
predictors.
It probably there are also early clinical symptoms or in treatment that can be very
informative, in patient receiving oxaliplatine. A key neurotoxicity is a good example that
these patients may develop called ingesthesia, cramps, or vesicles shortly after infusion,
and these symptoms are often transient, but they are not irrelevant.
severe prolonged acute oxaliplatine neurotoxicity can identify patients at higher risk of chronic
oxaliplatine neuropathy later in the course of treatment, for example.
But similarly, in patients with faculty tax cell and acute pain syndrome, maybe informative.
And it usually appears within the first days of treatment with muscle and joint pain that
picks around the three and then improves. And patients with more intense symptoms, we
know that they will be more likely to develop persistent sensory neuropathy. So chronic
clinical symptoms are not only adverse effects, they may also contain predictive information.
The second route is new physiological biomarkers, and nerve conduction studies can detect subclinical
nerve damage before symptoms are obvious. And the typical pattern in CIPN is a reduction
in sensory nerve action potentials with relatively preserved motor responses, which is consistent
with predominantly sensory axonal neuropathy. This is particularly useful in oxaliplatine
induced neuropathy, where longitudinal studies have shown that early changes in sensory nerves,
especially the dorsal subtle and radial nerves, and help predict neurological outcome after
at the end of treatment. But their limitation, however, is practical and nerve conduction
studies require a clean mind, training personnel, and ideally baseline measurements for comparison.
So they are informative, but they are not always easy to implement in a routine oncology
practice, especially if we want to monitor large number of patients repeatedly.
The third group is blood-based biomarkers, and genetic markers having wireless floor,
but today, no genetic marker is thoroughly validated for clinical use, and other candidates
include NSL or neurotrophic factors such as NGF or BDNF, because they may re-slend nerve
injury or reduce regenerative capacity of the nerve.
And also, my metabolism can meet the convalescent markers can be interesting, because my convalescent
functions and oxidative stress are central mechanisms in CIPN.
And finally, I would like to talk about imaging biomarkers, and high-resolutional dorsal
and magnetic resonance neuropathy can show structural changes in peripheral nerves, but
thus, and availability, they meet their routine use, though.
However, a very interesting and more accessible approach is the use of protein-city scans
to assess body composition, particularly circopenia.
And this is relevant, because many contributions already undergo city scans as part of their
oncology there, so we can potentially reduce existing images to extract additional information
about skeletal muscle mass.
Circopenia may influence chemotherapy toxicity, because a standard chemotherapy dosing is usually
based on body surface areas, using height and weight, but this does not capture body
composition.
For example, two patients may have the same body weight or BMI, but very different muscle
mass, which may affect the pharmacokinetics of antineoplastic agents.
So in our racing war, for example, we have already evaluated these regimen circopenia,
and we identified that it was associated with the development of clinically relevant CIPN.
The main finding of our war was that between the circopenia was associated with 2.4 to
1.5, all higher odds of clinically relevant CIPN.
And to sum up, I would like to say that today, no single biomarker will probably be enough.
Thank you so much, Rosen, for that great overview.
Really, a very useful insight to understand a bit better the world of biomarkers, and
stemming out from this reasoning.
In your opinion, what is limited in the past over ability to identify and validate genetic
risk factors to predict the development of CIPN?
I would say that one of the male mutations has been that CIPN represent a complex phenotype.
We often use the term chemo-serpent use for neuropathy in a general way, but in reality
neuropathy induced by pachytaxyl, oxaliplatin, or vortusomy, may not represent exactly the
same biological process.
These drugs affect the birth of other systems to different mechanisms, with different time
being different reversility and different clinical patterns.
So that is already a challenge for genetics.
If we mix different drugs, tumor types, doses, and scandals in the same analysis, the genetics
sign all becomes diluted.
Then a variant that might be irrelevant for toxicity may not necessarily be relevant for
oxaliplatin in this neurotoxicity.
So one of the lessons, in my opinion, from the field, is that we need to be much more
drug-specific when we study genetic risk.
And the second implementation has been powdered neuropathy phenotype is defined.
Human studies have used patient-reported symptoms, other used clinical-weight toxicity scales,
neurological examination, or nerve conduction studies.
So these are all valuable measures, but they are gut-equivalent.
If the outcome is not harmonized, even the real genetic association may be difficult
to reproduce.
And it is why many pharmacogenetic findings in CIPN have been inconsistent.
The studies also had methodological limitations, heterogeneous definitions of CIPN, and assessment
tools that were not always sufficiently reproducible.
And also there is an issue of statistical power, for most common genetic variants, the
effect of a single polymorphism is usually modest.
So we need large cohorts and independent rebukation.
In CIPN, many studies have been relatively small, exploratory, or raised on candidate
chains.
And this increases the resistance.
false positive findings and makes it difficult to know whether a signal is real or is generally
related to the specific population studied. We also have many confunding factors like comorbidities,
age, drug factors with ten influence, the risk of neuropathy, and if these are not carefully
controlled, they can blur the interpretation of genetic data. So all those several candidate
variants can be proposed, including variants in gen related to eye channels, neuronal receptors,
and metabolic pathways. As you know, a specific polymorphism has been validated enough to be
routinely to predict CFP and clinical practice. And to conclude, for me, the future of genetics and
CFP and it's not to look for one variant in isolation, it's to integrate genetic data into larger
better phenotype at drug-specific cohorts, and then combine genetics with clinical receptors
and other biomarkers. Thank you so much for this clear cut to review.
Thank you. You mentioned earlier about neurosurlement light chain as a potential biomarker in CIPN.
Can you discuss a bit about the potential utility of NFL in CIPN, including the differences between
different chemotherapy classes? Yes, of course. Yeah, and neurosurlement light chain, or NFL,
is a very interesting biomarker in CIPN because it gives us a biological sign-up of neuro-axonal
injury. And this hits very well with what we know about chemotherapy because CIPN is maybe an
axonal neuropathy. One practical advantage is that contributions already have regular blood tests
during chemotherapy. So adding a biomarker, such as NFL, would be relatively easy compared with
other techniques. So it could not require a complex or invasive procedure, and it could be repeated
over time. This is important because CIPN is a dynamic process, and we do not only want to know
whether neuropathy is present at one single time point, we want to understand whether nerve
damage is progressing, stabilizing, or recovering. So the potential utility of NFL is that it could
provide a more objective measure of neurodomage, complementing what we do obtain from symptoms,
neurological examination, clinical skills, or neuro-conditioning studies. And this is a relevant
because in current practice, we often react when the patient already reports symptoms, such as
numbness, tingling pain, or functional impairment. But at that point, some degree of nerve injury
may already be established. So a blunt biomarker could help us detect ongoing axonal injury
earlier and in a more objective way. The recent mask narrative review identified 11
technical studies mostly conducted in women with breast cancer, suggesting that, as a serum
near filaments, tend to rise during treatment with neurotoxic chemotherapy and that partly increases
often after the first few cycles or after two or three doses only, may be associated with later
CIPN similarity. In fact, in our studies, we have seen that NFL levels increase during treatment
with neurotoxic chemotherapy and then this increase correlates with the severity of neuropathy
and with neurophysiological abnormalities. For example, in patients who did with witty
peptidaxyl, thyrin, NFL levels were associated with more CIPN or peptidaxyl induced spray from
neuropathy. And we also observed that early imprisonment in NNSL after the first week's self-treatment
would help identify patients at higher risk of developing clinical or relevant neuropathy later on.
So this doesn't mean that NFL should replace clinical evaluation and I think this is an important
point. NFL is not a biomarker of symptoms or pain specifically. It is a biomarker of axonal
injury. So if a patient has neuropathic pain, NFL may not tell us the whole story or the pain
phenotype. It tells us more about whether there is an online structural nerve damage. And for that
reason, it should complement the patient's symptoms and neurological examination or even neurophysiology
when you do it. Another key point about NFL is that doesn't behave exactly the same across
all chemotherapy classes. That same, such as peptidaxyl, may produce relatively early and
marketing increases in the NFL probably reflecting axonal injury during treatment. However,
platinum compounds such as oxalicatin or cisplatin may show a different temper of profile.
In our recent work, we also observed that NFL rises during treatment and tends to decline during
recovery, but the magnitude and timing of these changes deferred among Asians. So this means that
the future clinical use of NFL probably will not be based on one universal threshold for all
patients and all drugs. More likely, we will need drug-specific cutouts, longitudinal
measurements at the specific time points and interpretation according to each baseline NFL
levels, treatment exposure and clinical context. So in summary, I see NFL as a very attractive
biomarker because it's blood-based, objective, and repeatable. It could help us monitor
near-toxicity more precisely and possibly detect axonal injury before neuropathy becomes severe.
But it should be integrated into a broader clinical framework not used as a stand-alone decision tool.
Fantastic, thank you so much. A very specific insight that inspired me. And considering all the
opportunities and pitfalls that you mentioned, do you think that there is prospect for a
novel risk prediction algorithm for CIPN, incorporating clinical risk factors, genetic markers,
and other biomarkers in your opinion? Yes, I just think there is a real feature for risk
prediction algorithms in CIPN. They could help us identify vulnerable patients earlier,
monitor near-toxicity more objectively and personalize treatment before nerve damage
because CIPNs are reversible. But they could be cautious about expecting one
tempoli universal model that works for every patient and every chemotherapy agent.
In my opinion, the future is probably not one general learning, but for said pain as a whole,
but rather, drug-specific are drop-adapted prediction models.
This is because, I said, actually, that celloccipitalia, vein crescine, or other neurotoxic agents
can all cause neuropathy, but mechanisms and timing, I said, are not the same. And this is important
to be keep in mind. I think that the models should integrate several layers of information.
First, we have the baseline clinical risk profile, like age, or persistent neuropathy, or even not
body composition, such as circopenia. And these factors may not be sufficient or not alone,
but it helps to define the patient's baseline vulnerability.
Ideally, genetic predators should also be included if available. In fact, in oncology, we already
have examples where pharmacogenetics can guide treatment decisions such as the PYD variants for
open-medium toxicity, and having something similar for said pain could be extremely valuable.
Importantly, the algorithm should also include treatment-related variables, particularly the
specific chemotherapy, and the cumulative dose and those intensity. And these are essential,
because neurotoxicity is strongly influenced by drug exposure. And third, we should also include
early warnings, same signs, during treatment. Some of these are clinical, such as acute
oxaliplatin, or pactyltexyl neurotoxicity. Others could be biological or neurophysiology,
enough connection studies for adults. There is a series where blood biomarkers, such as NFL,
become especially interesting, because they could provide a practical and objective
signal of ongoing axonal injury in real time. Because in my view, the most useful algorithm
should not be static score calculated only with four chemotherapy starts. It should be dynamic,
and updated during treatment, as new information becomes available. Same terms,
functional impact, NFL changes, and of course, I know that I know this is not following
the realistic yet, but several groups are on the wall and are working a collaborative
way together to identify the different elements that could eventually lead to an ideal,
predictive model for using clinical practice. Obviously, these models will need to be
prospectively validated, adapted to each chemotherapy class, and designed to support
Pindical Judgment.
but not to replace it. This is important. Thank you so much. I totally agree with you and
this could be the opportunity to start the collaboration and the study on this topic.
Yes, of course. Thank you a little bit along this line. What do you think at the moment is the
most promising avenue for future research in this field? For me, one of the most promising lines
of research in CPN is the development of integrated and clinically useful prediction models. Of course,
I do not think the featuring is about finding one perfect biomarker that will solve everything.
It is more about combining different pieces of information and making them useful for real
clinical decisions. Because CPN is complex and no single measurement captures the whole picture.
That is why we need large, well-senotide, cohorts of concentrations fall with
prospectively over time. And in my opinion, the question is not whether only one biomarker is
associated with CPN. The real question is whether combining these markers can help us predict
with a trace, monitor nerve damage during treatment and identify with a line to recover or develop
persistent neuropathy. And an important point is that prediction should be aligned to the null.
Based on risk, it's useful, but the patient's risk changes the treatment, as I've said,
not, for example, the development of acute oxaliplatine neurotoxicity or rising in the cells,
these changes should modify the risk estimate. So, future models should be dynamic,
broader than fix it. And therefore, this studies should therefore assess patients before treatment
during treatment and after treatment completion. And these could allow us to understand not only
who develops CPN, but also who recovers, who develops persistent neuropathy and who is at risk
of long-term functional impairment. And this is important because we must keep in mind that
persistent CPN is not only a toxicity rate. It can affect walking, balance, menal dexterity,
autonomy, sleep, quality of life, along, after-taxored treatment has ended. So, it's important to
consider that we need to focus on clinical actionability. It's not enough to show that a biomarker
is a statistically associated with neuropathy. The key question is whether it improves decision-making
and ultimately benefits patients. So, this also, in my opinion, means that future research should
involve both oncologists and neurologists. oncologists need tools that are practical and do not
compromise cancer efficacy. And neurologists, we can help with accurate phenotyping,
interpretation of neophysiology, and assessment of functional consequences. So,
the real approach should be technically feasible, biologically meaningful, and useful for shared
decision-making. To sum up, I would say that the most promising direction is a multimodal
and tutorial and personalized approach to CIPN prediction. And the goal is to move from reacting
once neuropathy is already established to identify vulnerable patients earlier and monitoring
nerve damage treatment while still preserving the efficacy of cancer therapy. Thank you so much,
Rosie. That was a fantastic answer and really outlined the need for collaboration across field in
this space. Thank you, Professor Belasco, for sharing your insights. It was a pleasure to have
you here as a guest today. Thank you for the invitation. You can find relevant papers in the show
notes and visit
[email protected] for more information about the peripheral net society.
Thank you for listening. See you next month.
The primary purpose of the peripheral nerve podcast is to meet the educational needs of
its listeners and address practice gaps by providing practice oriented and scientifically-based
education that will maintain an advanced competence and performance in the peripheral nerve field.
A diversity of opinions exists in the medical field and the views of the podcast faculty do
not represent those of the peripheral nerve society or constitute an endorsement by the peripheral
nerve society.